NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

Contributed by: ACCESS Newswire

Logo

Tags

AMEX:NNVC

Healthcare & Pharmaceutical

NanoViricides, Inc.

Product Announcements

More Like This

Novotech Releases Comprehensive Report on Oncolytic Virus Therapy

Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development

PR Newswire associated0

IRBM Reports Breakthrough in Zika Virus Drug Discovery

Innovative Molecules Expands Virology Pipeline with Novel EBV Antiviral Program

Novotech Report Reveals Global Surge in Infectious Disease Trials as Industry Nears 2,000 Studies Since 2020

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

PR Newswire associated0

Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir

Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2